scispace - formally typeset
J

Jules S. Jacob

Researcher at Brown University

Publications -  48
Citations -  3375

Jules S. Jacob is an academic researcher from Brown University. The author has contributed to research in topics: Bioadhesive & Drug delivery. The author has an hindex of 26, co-authored 48 publications receiving 3293 citations. Previous affiliations of Jules S. Jacob include Mansfield University of Pennsylvania.

Papers
More filters
Journal ArticleDOI

Biologically erodable microspheres as potential oral drug delivery systems

TL;DR: It is shown that engineered polymer microspheres made of biologically erodable polymers, which display strong adhesive interactions with gastrointestinal mucus and cellular linings, can traverse both the mucosal absorptive epithelium and the follicle-associated epithelia covering the lymphoid tissue of Peyer's patches.
Journal ArticleDOI

Double-walled polymer microspheres for controlled drug release

TL;DR: This work describes a one-step process for preparing double-walled polymer microspheres with diameters ranging from about 20 to 1,000 micrometres, which should make possible the engineering of highly specific drug-release properties.
Journal ArticleDOI

Nanosphere based oral insulin delivery

TL;DR: A specific formulation, 1.6% zinc insulin in poly(lactide-co-glycolide) (PLGA) with fumaric anhydride oligimer and iron oxide additives has been shown to be active orally and able to control plasma glucose levels when faced with a simultaneously administered glucose challenge.
Patent

Bioadhesive microspheres and their use as drug delivery and imaging systems

TL;DR: In this paper, the authors describe techniques for the fabrication of bio-adhesive microspheres, as well as a method for measuring bioadhesive forces between micro-spheres and selected segments of the gastrointestinal tract in vitro.
Journal Article

In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity.

TL;DR: The utility of biodegradable polymer microspheres as a clinically feasible alternative to systemic cytokine therapy and cytokine gene-modified cell vaccines for the treatment of neoplastic disease is established.